Cyclophosphamide for myasthenia gravis: a comeback?

Patients with refractory or high-risk myasthenia gravis (MG) respond poorly to conventional immunosuppressive therapy, requiring rescue therapies and often experiencing treatment toxicity. The study discussed in this podcast suggests that lower doses of cyclophosphamide can be effective and safe in people with MG, including older age. JNNP's podcast editor, Saima Chaudhry, is joined by Professor Carolina Barnett-Tapia, University of Toronto, University Health Network, who authors the editorial comment 'Cyclophosphamide for myasthenia gravis: a comeback?'( The original paper is also free to access: Please

You can listen to Cyclophosphamide for myasthenia gravis: a comeback? online on Radio and Podcast. Open the player on this page to stream the available audio.

Cyclophosphamide for myasthenia gravis: a comeback? is an episode from JNNP podcast by BMJ Group.

This episode is 37:58 long.

This episode was published on Apr 17, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from JNNP podcast when more episodes are available from the podcast feed.